Showing 121 - 140 results of 78,590 for search '(( 5 ((ppm decrease) OR (a decrease)) ) OR ((( 1 n decrease ) OR ( 5 we decrease ))))', query time: 1.28s Refine Results
  1. 121

    Table_3_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.docx by Xiao-yang Gong (13103400)

    Published 2022
    “…A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”
  2. 122

    Table1_Satisfaction With Governmental Risk Communication Both Increases and Decreases COVID-19 Mitigation Behaviours.docx by Darrick Evensen (13757068)

    Published 2023
    “…</p><p>Methods:Via a survey (N = 4,206) of representative samples of the general public in five European countries (Germany, Norway, Sweden, Switzerland, United Kingdom), we explore perceptions of a range of personal/public health, economic, and societal risks. …”
  3. 123

    Image_1_Chemical Similarity of Co-occurring Trees Decreases With Precipitation and Temperature in North American Forests.jpg by Brian E. Sedio (10875330)

    Published 2021
    “…We used untargeted metabolomics methods based on data generated with liquid chromatography-tandem mass spectrometry to identify, classify, and compare 13,480 unique foliar metabolites and to quantify the metabolomic similarity of species in each community with respect to the whole metabolome and each of five broad classes of metabolites. …”
  4. 124

    GSK343 decreased tumor stemness. by Laura V. Bownes (10276762)

    Published 2021
    “…(C) COA6 cells were treated with GSK343 (0, 5 μM) for 72 hours. qPCR demonstrated a significant decrease in mRNA abundance of known stemness markers Oct4, Nanog, and Sox2 following GSK343 treatment compared to untreated cells. …”
  5. 125
  6. 126

    Decreased activity of FASII favors the cold growth of the <i>ΔcshA</i> strain. by Vanessa Khemici (814639)

    Published 2020
    “…<i>fapR</i> mRNA levels were quantified by RT-qPCR using 16S rRNA as reference gene on total RNAs extracted from <i>wt</i> strain (PR01), <i>ΔcshA</i> strain (PR01-ΔcshA), and suppressor strains <i>ΔcshA/accC</i><sup><i>M385V</i></sup> (C51), <i>ΔcshA/accC</i><sup><i>T183I</i></sup> (sup30), <i>ΔcshA/accD</i><sup><i>F253V</i></sup> (sup17), <i>ΔcshA/accD</i><sup><i>A164V</i></sup> (sup16), <i>ΔcshA/birA</i><sup><i>D320F-FsX28</i></sup> (C58), <i>ΔcshA/birA</i><sup><i>R280stop</i></sup> (sup1) and <i>ΔcshA/bioY</i><sup><i>P123R-FsX1</i></sup> (C66), all at exponential growth phase in MH medium at 25°C. n = 5 for <i>ΔcshA</i>, <i>4 for wt</i> and 3 for all others. …”
  7. 127
  8. 128

    Image_1_Decreased Opioid Consumption in Bone Marrow Harvest Patients Using Quadratus Lumborum Blocks in a Standardized Protocol.PDF by Nicole C. McCoy (12459036)

    Published 2022
    “…The implementation group showed significantly reduced median intraoperative (20.0 mg vs. 0.0 mg; p < 0.001) and total opioid consumption (20.5 mg vs. 0.0 mg; p < 0.001). The number of patients who received any opioids decreased from 84.2% (16/19) before implementation to 23.1% (3/13) after implementation.…”
  9. 129
  10. 130
  11. 131
  12. 132
  13. 133
  14. 134

    DataSheet_1_NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer.zip by Xiao-yang Gong (13103400)

    Published 2022
    “…A total of 469 genomic alterations were detected in 211 distinct cancer-relevant genes, and the genes found to be mutated in more than five patients (>10%) included tumor protein p53 (TP53, 78.5%), FAT atypical cadherin 1 (FAT1, 26%), LDL receptor related protein 1B (LRP1B, 19%), cyclin dependent kinase inhibitor 2A (CDKN2A, 17%), tet methylcytosine dioxygenase 2 (TET2, 17%), notch receptor 1 (NOTCH1, 12%) and neuregulin 1 (NRG1, 12%). …”
  15. 135
  16. 136
  17. 137
  18. 138
  19. 139
  20. 140